AstraZeneca reported adjusted earnings per share of $1.10 for the fourth quarter, surpassing analyst forecasts of $1.04. The oncology division delivered 25% year-over-year growth, with Tagrisso and Imfinzi sales reaching a combined $4.5 billion and offsetting weakness in respiratory and cardiovascular products.

For 2025, AstraZeneca achieved revenue of $46.1 billion, up 9% from the prior year. Growth was supported by the oncology portfolio and contributions from its recently spun-off vaccine unit, while legacy product declines were partially offset by price increases and volume gains.

Management reiterated commitment to the oncology pipeline, highlighting Phase III readouts for two antibody-drug conjugates expected in H2 2026. Full-year 2026 revenue growth guidance was set at a mid-to-high single-digit percentage, reflecting anticipated launches of targeted therapies in lung and breast cancer.